Mecasermin rinfabate clinical trials
Also written rhIGF-I/rhIGFBP-3.
How each study uses mecasermin rinfabate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 12 Dec 2005 · IPLEX · BLA 021884 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Insmed Incorporated (2) · OHB Neonatology Ltd. (1) · Shire (1)
Studies
Open first, then newest update. How each study uses mecasermin rinfabate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsActive, not recruitingPhase 2OHB Neonatology Ltd.NCT03253263Written as OHB-607
- Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1CompletedPhase 2Insmed IncorporatedNCT00577577Written as rhIGF-I/rhIGFBP-3
- IGF-1/IGFBP3 Prevention of Retinopathy of PrematurityCompletedPhase 2ShireNCT01096784Written as rhIGF-I/rhIGFBP-3
- IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron SyndromeCompletedPhase 2/3Insmed IncorporatedNCT00368173Written as rhIGF-I/rhIGFBP-3
Codes
What other systems call mecasermin rinfabate · ClinicalTrials.gg INT017429
- UNII (FDA) NZ8M50KKRGMECASERMIN RINFABATEOne source FDA
- RxNorm 616877One source FDA
- NCI Thesaurus C174773Mecasermin RinfabateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NZ8M50KKRG | MECASERMIN RINFABATE | One source FDA |
| RxNorm | 616877 | — | One source FDA |
| NCI Thesaurus | C174773 | Mecasermin Rinfabate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.